Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world's leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health.
- SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world's leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health.
- Blacksmith and Zoetis will collaborate to discover and develop novel antibiotics to selectively target bacteria for animal health," said Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith.
- "As part of our commitment to reduce the dependency on antibiotic classes shared with human health, we are pleased to leverage our veterinary expertise along with our extensive collection of pathogens in this collaboration with Blacksmith," said Dr. Jeff Watts, Research Director, External Innovation at Zoetis.
- "Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock."